On September 19, 2023, Inhibrx, a leading biotechnology company in the clinical-stage, made an announcement regarding Chiesi Farmaceutici S.p.A’s decision not to exercise its option for the ex-North American rights concerning the development and commercialization of INBRX-101. INBRX-101 is a highly promising therapeutic candidate specifically designed for the treatment of Alpha-1 antitrypsin deficiency (AATD).
Under the agreement between Inhibrx and Chiesi, the latter was granted an exclusive option to license, develop, and commercialize INBRX-101 outside of the United States and Canada. However, as of now, Chiesi has chosen not to pursue this opportunity.
Nevertheless, Inhibrx remains in full possession of the rights to INBRX-101 for the treatment of AATD outside of the United States and Canada. This decision allows Inhibrx to explore alternative avenues and partnerships to further develop and bring this potentially groundbreaking treatment to patients worldwide.
Updated on: 29/09/2023
Debt to equity ratio: Strong Buy
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Strong Sell
1:00 PM (UTC)
Date:25 September, 2023
There are no analysts data to display
INBX Stock Performance: Stable Opening with Concerning Financial Indicators
INBX is a biotechnology company in the Health Technology sector. On September 19, 2023, the stock opened at $20.69, slightly lower than the previous day’s close of $21.04. Throughout the day, the stock had a trading range between $20.36 and $21.06. The trading volume was relatively low at 8,767 shares, compared to the average volume of 407,347 shares over the past three months. The market capitalization of INBX is $915.7 million.
The earnings growth for the last year was -68.32%, indicating a significant decrease in profitability. The earnings growth for this year is also negative at -14.60%.
The revenue growth for the last year was -69.43%, reflecting a substantial decrease in the company’s sales. INBX’s financial performance is concerning, with a negative net profit margin of -6,667.86%. This indicates that the company’s expenses exceed its revenue, resulting in a significant loss. The P/E ratio is not available (NM), and the price/sales ratio is high at 453.75. The price/book ratio is 15.74, suggesting that the stock may be overvalued.
The next reporting date for INBX is November 7, 2023, when the company will release its financial results for the upcoming quarter. The EPS forecast for this quarter is -$1.06, indicating a loss per share. INBX reported an annual revenue of $2.2 million and a significant annual loss of -$145.2 million in the previous year.
In conclusion, INBX’s stock performance on September 19, 2023, was relatively stable, with a slight decrease in the opening price compared to the previous day’s close. However, the company’s financial indicators, such as earnings growth, revenue growth, and net profit margin, suggest that INBX is facing significant challenges in terms of profitability. Investors should closely monitor the company’s upcoming financial reports to assess its future prospects.
Inhibrx Inc (INBX) Stock Soars with Positive Price Forecasts and Unanimous Buy Rating in September 2023
On September 19, 2023, Inhibrx Inc (INBX) experienced positive stock performance. The 12-month price forecasts from four analysts for INBX had a median target of $50.00, with a high estimate of $60.00 and a low estimate of $27.00. This represents a significant increase of 140.85% from the last price of $20.76.
The current consensus among the four polled investment analysts is to buy stock in Inhibrx Inc. This rating has remained steady since September.
In terms of financial performance, Inhibrx Inc reported earnings per share of -$1.06 for the current quarter. However, it is important to note that the company reported $0.00 in sales for the same period. The reporting date for these financials is set for November 7.
These figures suggest that despite the negative earnings per share, investors and analysts remain optimistic about the future prospects of Inhibrx Inc.
Inhibrx Inc is a biotechnology company that focuses on the development of therapeutic antibodies for the treatment of various diseases. The positive outlook for the company’s stock can be attributed to potential breakthroughs in its pipeline and promising clinical trial results.
Investors should carefully consider their investment decisions and conduct thorough research before making any investment in Inhibrx Inc or any other stock. While the consensus among analysts is positive, it is important to remember that the stock market is inherently unpredictable, and there are always risks involved in investing.
In conclusion, on September 19, 2023, Inhibrx Inc’s stock performed well, with positive price forecasts from analysts and a unanimous buy rating. Despite reporting negative earnings per share for the current quarter, the company’s potential for future growth is reflected in the high median target price. Investors should exercise caution and conduct their due diligence before making any investment decisions.